[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100433270":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":38,"locations":48,"responsibleParty":99,"collaborators":102,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":27,"eligibilityCriteria":116,"healthyVolunteers":112,"sex":117,"minAge":118,"maxAge":27,"enrollmentInfo":119,"targetDuration":27,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":27,"overallStatus":64,"whyStopped":27,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hypertonic saline","EXPERIMENTAL","Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.",[13],"Drug: Hypertonic saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of Care","ACTIVE_COMPARATOR","Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS\u002FIDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.",[19,20,21],"Drug: Azithromycin","Drug: Ethambutol","Drug: Rifampin",[23,28,32,35],{"type":24,"name":9,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Nebulizing with 7% hypertonic saline twice daily for 12 weeks.",[9],null,{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Azithromycin","Standard of care",[15],{"type":24,"name":33,"description":30,"armGroupLabels":34,"otherNames":27},"Ethambutol",[15],{"type":24,"name":36,"description":30,"armGroupLabels":37,"otherNames":27},"Rifampin",[15],[39,44],{"name":40,"role":41,"phone":42,"phoneExt":27,"email":43},"Daniel Bouchat","CONTACT","503-494-1859","johdanie@ohsu.edu",{"name":45,"role":41,"phone":46,"phoneExt":27,"email":47},"Alyssa Schroeder","503-494-2136","schroeder@ohsu.edu",[49,62,80],{"facility":50,"status":51,"city":52,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":27},"NYU Langone Health","ACTIVE_NOT_RECRUITING","New York","10016","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-74.00597,40.71427,{"lat":60,"lon":59},{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":54,"countryCode":55,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Oregon Health & Science University","RECRUITING","Portland","Oregon","97239",{"type":57,"coordinates":69},[70,71],-122.67621,45.52345,{"lat":71,"lon":70},[74,75,77],{"name":45,"role":41,"phone":46,"phoneExt":27,"email":47},{"name":40,"role":41,"phone":76,"phoneExt":27,"email":43},"(503) 494-2568",{"name":78,"role":79,"phone":27,"phoneExt":27,"email":27},"Kevin L Winthrop, MD, MPH","PRINCIPAL_INVESTIGATOR",{"facility":81,"status":64,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"University Health Network","Toronto","Ontario","ON M5G","Canada","CA",{"type":57,"coordinates":88},[89,90],-79.39864,43.70643,{"lat":90,"lon":89},[93,97],{"name":94,"role":41,"phone":95,"phoneExt":27,"email":96},"Matty Mehrabi","416-603-5726","Matty.Mehrabi@uhn.ca",{"name":98,"role":79,"phone":27,"phoneExt":27,"email":27},"Theodore Marras, MD",{"type":79,"investigatorFullName":100,"investigatorTitle":101,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Kevin Winthrop","Principal Investigator",[103,106,108],{"name":104,"class":105},"NTM Info & Research, Inc.","UNKNOWN",{"name":107,"class":6},"University Health Network, Toronto",{"name":109,"class":6},"New York University","100433270","phase-4-hypertonic-saline-for-mac-100433270",false,"NCT04921943","Hypertonic Saline for MAC","Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease","Inclusion Criteria:\n\n* At least 2 positive MAC sputum cultures in the last 12 months with at least one AFB positive sputum obtained within 12 weeks prior to randomization\n* Meet American Thoracic Society (ATS)\u002F Infectious Disease Society of America (IDSA) 2007 pulmonary clinical disease criteria\\[1\\]\n* Age 18 and older\n* Diagnosis of Bronchiectasis and\u002For bronchiectatic findings evident on chest CT report\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Any patient who is unwilling or unable to provide consent or to comply with this protocol\n* Cavitary NTM disease\n* Patients who are currently taking or within the prior 6 months received any of the following: bedaquiline, or any component of ATS\u002FIDSA multi-drug recommended therapy (macrolide, ethambutol, rifampin) for MAC treatment\n* Diagnosis of HIV\n* Diagnosis of Cystic fibrosis\n* Active pulmonary tuberculosis, fungal, or nocardial disease requiring treatment at screening\n* Current use of chronic systemic corticosteroids at doses of 15 mg\u002Fday for more than 3 months\n* Prior lung or other solid organ transplant","ALL","18 Years",{"count":120,"type":121},50,"ESTIMATED","INTERVENTIONAL",[124],"PHASE4","The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.",[127,128],"Nontuberculous Mycobacterial Lung Disease","Nontuberculous Mycobacterium Infection","2025-08-12",{"date":131,"type":132},"2025-08-15","ACTUAL",{"date":134,"type":132},"2021-05-18",{"date":136,"type":121},"2025-12-31",{"name":5,"class":6},3]